Anupam Rama
Stock Analyst at JP Morgan
(3.54)
# 904
Out of 4,711 analysts
247
Total ratings
43.37%
Success rate
6.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Overweight | $66 → $36 | $14.55 | +147.42% | 10 | Dec 19, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $105 → $102 | $44.22 | +130.66% | 2 | Nov 21, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $33 → $38 | $13.08 | +190.52% | 8 | Nov 21, 2024 | |
| COGT Cogent Biosciences | Maintains: Overweight | $19 → $21 | $7.84 | +167.86% | 4 | Nov 14, 2024 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $12 | $4.16 | +188.46% | 6 | Nov 12, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $16 → $17 | $9.80 | +73.47% | 13 | Nov 12, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Underweight | n/a | $0.83 | - | 7 | Nov 11, 2024 | |
| VERA Vera Therapeutics | Maintains: Overweight | $72 → $75 | $42.60 | +76.06% | 8 | Nov 5, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $39 → $40 | $20.59 | +94.27% | 3 | Nov 5, 2024 | |
| ZLAB Zai Lab | Maintains: Overweight | $38 → $44 | $26.72 | +64.67% | 11 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $84.22 | +48.42% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.51 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $12.49 | +36.11% | 7 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $23 | $17.18 | +33.88% | 3 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $57 | $33.21 | +71.64% | 15 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $35.59 | +91.06% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $31 | $6.10 | +408.20% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $25.61 | +157.71% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $26.49 | +62.33% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $173 → $181 | $135.42 | +33.66% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $5.61 | +78.25% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $36 | $12.79 | +181.47% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.95 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $118.97 | +47.10% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.09 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.23 | +148.57% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $18 | $8.21 | +119.24% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.40 | - | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $1.19 | +656.30% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.65 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.58 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $11.40 | +2,092.98% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $48.87 | +18.68% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $9.59 | +25.13% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $7.34 | +404.09% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $41.49 | +32.56% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $2.54 | +1,002.36% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $35.42 | +52.46% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.69 | +6,400.07% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $23.99 | +12.55% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $7.42 | +439.08% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $245.44 | -44.18% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $8.28 | +371.01% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $5.63 | +752.58% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $12.72 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.87 | +1,963.51% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.24 | +1,239.29% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $46.24 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.45 | - | 2 | Jul 21, 2017 |
AnaptysBio
Dec 19, 2024
Maintains: Overweight
Price Target: $66 → $36
Current: $14.55
Upside: +147.42%
Ultragenyx Pharmaceutical
Nov 21, 2024
Maintains: Overweight
Price Target: $105 → $102
Current: $44.22
Upside: +130.66%
Syndax Pharmaceuticals
Nov 21, 2024
Maintains: Overweight
Price Target: $33 → $38
Current: $13.08
Upside: +190.52%
Cogent Biosciences
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $7.84
Upside: +167.86%
Solid Biosciences
Nov 12, 2024
Maintains: Overweight
Price Target: $15 → $12
Current: $4.16
Upside: +188.46%
Amicus Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $9.80
Upside: +73.47%
RAPT Therapeutics
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.83
Upside: -
Vera Therapeutics
Nov 5, 2024
Maintains: Overweight
Price Target: $72 → $75
Current: $42.60
Upside: +76.06%
Kiniksa Pharmaceuticals International,
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $20.59
Upside: +94.27%
Zai Lab
Oct 21, 2024
Maintains: Overweight
Price Target: $38 → $44
Current: $26.72
Upside: +64.67%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $84.22
Upside: +48.42%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.51
Upside: -
Sep 24, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $12.49
Upside: +36.11%
Sep 13, 2024
Maintains: Overweight
Price Target: $20 → $23
Current: $17.18
Upside: +33.88%
Sep 13, 2024
Maintains: Overweight
Price Target: $64 → $57
Current: $33.21
Upside: +71.64%
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $35.59
Upside: +91.06%
Aug 8, 2024
Maintains: Overweight
Price Target: $33 → $31
Current: $6.10
Upside: +408.20%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $25.61
Upside: +157.71%
Aug 7, 2024
Maintains: Overweight
Price Target: $46 → $43
Current: $26.49
Upside: +62.33%
Aug 7, 2024
Maintains: Overweight
Price Target: $173 → $181
Current: $135.42
Upside: +33.66%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $5.61
Upside: +78.25%
Aug 6, 2024
Maintains: Overweight
Price Target: $38 → $36
Current: $12.79
Upside: +181.47%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.95
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $118.97
Upside: +47.10%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.09
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.23
Upside: +148.57%
Mar 27, 2024
Maintains: Overweight
Price Target: $19 → $18
Current: $8.21
Upside: +119.24%
Dec 22, 2023
Downgrades: Underweight
Price Target: n/a
Current: $0.40
Upside: -
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $1.19
Upside: +656.30%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $8.65
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.58
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $11.40
Upside: +2,092.98%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $48.87
Upside: +18.68%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $9.59
Upside: +25.13%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $7.34
Upside: +404.09%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $41.49
Upside: +32.56%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $2.54
Upside: +1,002.36%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $35.42
Upside: +52.46%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.69
Upside: +6,400.07%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $23.99
Upside: +12.55%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $7.42
Upside: +439.08%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $245.44
Upside: -44.18%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $8.28
Upside: +371.01%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $5.63
Upside: +752.58%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $12.72
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.87
Upside: +1,963.51%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $2.24
Upside: +1,239.29%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $46.24
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.45
Upside: -